LOGIN  |  REGISTER
Viking Therapeutics

Upcoming FDA Catalyst Calendar

  • Sep 12

    BioCryst Pharmaceuticals (NASDAQ: BCRX) PDUFA Date

    Friday, September 12, 2025
    CompanyBioCryst Pharmaceuticals
    Stock QuoteNASDAQ: BCRX
    Study NameORLADEYO (berotralstat)
    TreatmentHereditary angioedema (HAE)
    StatusNew Drug Application (NDA)
    Catalyst DateSeptember 12, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Sep 26

    Cytokinetics (NASDAQ: CYTK) PDUFA Date

    Friday, September 26, 2025
    CompanyCytokinetics
    Stock QuoteNASDAQ: CYTK
    Study NameAficamten
    TreatmentSymptomatic obstructive hypertrophic cardiomyopathy (oHCM)
    StatusPhase 3
    Catalyst DateSeptember 26, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Sep 26

    Unicycive Therapeutics (NASDAQ: UNCY) PDUFA Date

    Friday, September 26, 2025
    CompanyUnicycive Therapeutics
    Stock QuoteNASDAQ: UNCY
    Study NameOxylanthanum Carbonate (OLC)
    TreatmentSymptomatic obstructive hypertrophic cardiomyopathy (oHCM)
    StatusPhase 1
    Catalyst DateJune 28, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Oct 7

    Jazz Pharmaceuticals (NASDAQ: JAZZ) PDUFA Date

    Tuesday, October 7, 2025
    CompanyJazz Pharmaceuticals
    Stock QuoteNASDAQ: JAZZ
    Study NameZepzelca (lurbinectedin)
    TreatmentRelapsed Small Cell Lung Cancer (SCLC)
    StatusPhase 3
    Catalyst DateOctober 7, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Oct 13

    Arcutis Biotherapeutics (NASDAQ: ARQT) PDUFA Date

    Monday, October 13, 2025
    CompanyArcutis Biotherapeutics
    Stock QuoteNASDAQ: ARQT
    Study NameZORYVE™ (roflumilast)
    TreatmentInhibitor of phosphodiesterase-4 (PDE4)
    Statussupplemental New Drug Application (sNDA)
    Catalyst DateOctober 13, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Oct 25

    Syndax Pharmaceuticals (NASDAQ: SNDX) PDUFA Date

    Saturday, October 25, 2025
    CompanySyndax Pharmaceuticals
    Stock QuoteNASDAQ: SNDX
    Study NameRevumenib
    TreatmentRelapsed/Refractory KMT2Ar Acute Leukemia
    Statussupplemental New Drug Application (sNDA)
    Catalyst DateOctober 25, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Oct 25

    Merck (NYSE: MRK) PDUFA Date

    Saturday, October 25, 2025
    CompanyMerck
    Stock QuoteNYSE: MRK
    Study Namesotatercept-csrk
    TreatmentIn adults with pulmonary arterial hypertension
    StatusBiologics License Applications (BLA) Priority Review
    Catalyst DateOctober 25, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Nov 9

    REGENXBIO (NASDAQ: RGNX) PDUFA Date

    Sunday, November 9, 2025
    CompanyREGENXBIO
    Stock QuoteNASDAQ: RGNX
    Study NameRGX-121
    TreatmentMPS II (Hunter Syndrome)
    StatusBiologics License Applications (BLA)
    Catalyst DateNovember 9, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Nov 30

    Ascendis Pharma (NASDAQ: ASND) PDUFA Date

    Sunday, November 30, 2025
    CompanyAscendis Pharma
    Stock QuoteNASDAQ: ASND
    Study NameTransCon CNP
    TreatmentIn Children with Achondroplasia
    StatusNew Drug Application (NDA)
    Catalyst DateNovember 30, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Nov 30

    Kura Oncology (NASDAQ: KURA) PDUFA Date

    Sunday, November 30, 2025
    CompanyKura Oncology
    Stock QuoteNASDAQ: KURA
    Study NameZiftomenib
    TreatmentTreatment of genetically defined AML patients with high unmet need
    StatusNew Drug Application (NDA)
    Catalyst DateNovember 30, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Dec 5

    Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

    Friday, December 5, 2025
    CompanyBristol-Myers Squibb
    Stock QuoteNYSE: BMY
    Study NameBreyanzi (lisocabtagene maraleucel)
    TreatmentSecond-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL)
    Statussupplemental Biologics License Applications (sBLA)
    Catalyst DateDecember 5, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Dec 13

    Milestone Pharmaceuticals (NASDAQ: MIST) PDUFA Date

    Saturday, December 13, 2025
    CompanyMilestone Pharmaceuticals
    Stock QuoteNASDAQ: MIST
    Study NameEtripamil
    TreatmentFor Treatment in Paroxysmal Supraventricular Tachycardia
    StatusN/A
    Catalyst DateDecember 13, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Dec 15

    Innoviva (NASDAQ: INVA) PDUFA Date

    Monday, December 15, 2025
    CompanyInnoviva
    Stock QuoteNASDAQ: INVA
    Study NameZoliflodacin
    TreatmentFor the Treatment of Uncomplicated Gonorrhea
    StatusPhase 3
    Catalyst DateDecember 15, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Dec 16

    Aldeyra Therapeutics (NASDAQ: ALDX) PDUFA Date

    Tuesday, December 16, 2025
    CompanyAldeyra Therapeutics
    Stock QuoteNASDAQ: ALDX
    Study NameReproxalap
    TreatmentSmall-molecule modulator of RASP
    StatusNew Drug Application (NDA)
    Catalyst DateDecember 16, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Dec 26

    Cytokinetics (NASDAQ: CYTK) PDUFA Date

    Friday, December 26, 2025
    CompanyCytokinetics
    Stock QuoteNASDAQ: CYTK
    Study NameAficamten
    TreatmentSymptomatic obstructive hypertrophic cardiomyopathy (oHCM)
    StatusNew Drug Application (NDA)
    Catalyst DateDecember 26, 2025
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Jan 5

    Denali Therapeutics (NASDAQ: DNLI) PDUFA Date

    Monday, January 5, 2026
    CompanyDenali Therapeutics
    Stock QuoteNASDAQ: DNLI
    Study Nametividenofusp
    TreatmentFor the treatment of Hunter syndrome (MPS II)
    StatusBiologics License Applications (BLA)
    Catalyst DateJanuary 5, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Jan 10

    Atara Biotherapeutics (NASDAQ: ATRA) PDUFA Date

    Saturday, January 10, 2026
    CompanyAtara Biotherapeutics
    Stock QuoteNASDAQ: ATRA
    Study NameTabelecleucel (tab-cel)
    TreatmentPost-Transplant Lymphoproliferative Disease (PTLD)
    StatusBiologics License Applications (BLA)
    Catalyst DateJanuary 10, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Jan 31

    Aquestive Therapeutics (NASDAQ: AQST) PDUFA Date

    Saturday, January 31, 2026
    CompanyAquestive Therapeutics
    Stock QuoteNASDAQ: AQST
    Study NameAnaphylm
    TreatmentFor epinephrine prodrug candidate product
    StatusNew Drug Application (NDA)
    Catalyst DateJanuary 31, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Feb 21

    Vanda Pharmaceuticals (NASDAQ: VNDA) PDUFA Date

    Saturday, February 21, 2026
    CompanyVanda Pharmaceuticals
    Stock QuoteNASDAQ: VNDA
    Study NameBysanti
    TreatmentFor the Treatments of Acute Bipolar I Disorder and Schizophrenia
    StatusNew Drug Application (NDA)
    Catalyst DateFebruary 21, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Feb 25

    Eton Pharmaceuticals (NASDAQ: ETON) PDUFA Date

    Wednesday, February 25, 2026
    CompanyEton Pharmaceuticals
    Stock QuoteNASDAQ: ETON
    Study NameET-600
    TreatmentFor the treatment of an endocrinology
    StatusNew Drug Application (NDA)
    Catalyst DateFebruary 25, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Mar 6

    Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

    Friday, March 6, 2026
    CompanyBristol-Myers Squibb
    Stock QuoteNYSE: BMY
    Study NameDeucravacitinib
    TreatmentModerate to severe plaque psoriasis
    Statussupplemental New Drug Application (sNDA)
    Catalyst DateMarch 6, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Mar 6

    Lantheus (NASDAQ: LNTH) PDUFA Date

    Friday, March 6, 2026
    CompanyLantheus
    Stock QuoteNASDAQ: LNTH
    Study NamePiflufolastat F 18 (formerly 8F-DCFPyL)
    TreatmentBiochemically Recurrent Prostate Cancer (CONDOR)
    StatusNew Drug Application (NDA)
    Catalyst DateMarch 6, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here
  • Jun 5

    Arvinas (NASDAQ: ARVN) PDUFA Date

    Friday, June 5, 2026
    CompanyArvinas
    Stock QuoteNASDAQ: ARVN
    Study NameVepdegestrant
    TreatmentFor ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
    StatusNew Drug Application (NDA)
    Catalyst DateJune 5, 2026
    CatalystPDUFA Date
    AnnouncementRead More
    WebsiteClick Here

Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE